Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

The approach employed by the research team could be used against other diseases—including COVID-19 and influenza.

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

Researchers at MIT and the Scripps Research Institute have shown that they can generate a strong immune response to HIV with ...

Health authorities in Zambia have halted a planned clinical trial for an HIV vaccine after the United States withdrew funding ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

By C.J. Atkins Just in time for Pride month, President Donald Trump and Health Secretary Robert F. Kennedy, Jr., have ...

A supercharged HIV vaccine could offer strong protection with just one injection, a study in mice has indicated. Developed by researchers from the Massachusetts Institute of Technology (MIT ...

Researchers have shown that a tiny nanoparticle formulation of saponin, along with an inflammation-promoting molecule called ...